Regulation of ABC Transporters Blood-Brain Barrier. The Good, the Bad, and the Ugly.

Advances in Cancer Research

Volumn 125, Issue , 2015, Pages 43-70

  Miller, David S ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Breast cancer related protein; Multidrug resistance associated proteins; P glycoprotein; Transporter activity; Transporter expression

Indexed keywords

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATE; BREAST CANCER RESISTANCE PROTEIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN; TRANSCRIPTION FACTOR; XENOBIOTIC AGENT; ABCG2 PROTEIN, HUMAN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; TUMOR PROTEIN;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY ENDOTHELIAL CELL; CENTRAL NERVOUS SYSTEM; DRUG DELIVERY SYSTEM; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; POLLUTANT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BIOAVAILABILITY; BIOSYNTHESIS; BRAIN; HUMAN; IMMUNOLOGY; METABOLISM; MOUSE; PHYSIOLOGY; RAT; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; HUMANS; INFLAMMATION; MICE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; OXIDATIVE STRESS; P-GLYCOPROTEIN; RATS;

EID: 84921829329     PISSN: 0065230X     EISSN: 21625557     Source Type: Book Series    
DOI: 10.1016/bs.acr.2014.10.002     Document Type: Chapter

References (69)

1. Abbott N.J. Blood-brain barrier structure and function and the challenges for CNS drug delivery. Journal of Inherited Metabolic Disease 2013, 36:437-449.
2. Abbott N.J., Friedman A. Overview and introduction: The blood-brain barrier in health and disease. Epilepsia 2012, 53(Suppl. 6):1-6.
3. Abbott N.J., Patabendige A.A., Dolman D.E., Yusof S.R., Begley D.J. Structure and function of the blood-brain barrier. Neurobiology of Disease 2010, 37:13-25.
4. Agarwal S., Hartz A.M., Elmquist W.F., Bauer B. Breast cancer resistance protein and P-glycoprotein in brain cancer: Two gatekeepers team up. Current Pharmaceutical Design 2011, 17:2793-2802.
5. Barakat S., Demeule M., Pilorget A., Regina A., Gingras D., Baggetto L.G., et al. Modulation of p-glycoprotein function by caveolin-1 phosphorylation. Journal of Neurochemistry 2007, 101:1-8.
6. Barakat S., Turcotte S., Demeule M., Lachambre M.P., Regina A., Baggetto L.G., et al. Regulation of brain endothelial cells migration and angiogenesis by P-glycoprotein/caveolin-1 interaction. Biochemical and Biophysical Research Communications 2008, 372:440-446.
7. Bauer B., Hartz A.M., Fricker G., Miller D.S. Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier. Molecular Pharmacology 2004, 66:413-419.
8. Bauer B., Hartz A.M., Lucking J.R., Yang X., Pollack G.M., Miller D.S. Coordinated nuclear receptor regulation of the efflux transporter, Mrp2, and the phase-II metabolizing enzyme, GSTpi, at the blood-brain barrier. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism 2008, 28:1222-1234.
9. Bauer B., Hartz A.M., Miller D.S. Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. Molecular Pharmacology 2007, 71:667-675.
10. Bauer B., Hartz A.M., Pekcec A., Toellner K., Miller D.S., Potschka H. Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Molecular Pharmacology 2008, 73:1444-1453.
11. Bauer B., Yang X., Hartz A.M., Olson E.R., Zhao R., Kalvass J.C., et al. In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation. Molecular Pharmacology 2006, 70:1212-1219.
12. Bendayan R., Lee G., Bendayan M. Functional expression and localization of P-glycoprotein at the blood brain barrier. Microscopy Research and Technique 2002, 57:365-380.
13. Brenn A., Grube M., Jedlitschky G., Fischer A., Strohmeier B., Eiden M., et al. St. John's Wort reduces beta-amyloid accumulation in a double transgenic Alzheimer's disease mouse model-role of P-glycoprotein. Brain Pathology 2014, 24:18-24.
14. Campos C.R., Schroter C., Wang X., Miller D.S. ABC transporter function and regulation at the blood-spinal cord barrier. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism 2012, 32:1559-1566.
15. Cannon R.E., Peart J.C., Hawkins B.T., Campos C.R., Miller D.S. Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:15930-15935.
16. Cartwright T.A., Campos C.R., Cannon R.E., Miller D.S. Mrp1 is essential for sphingolipid signaling to p-glycoprotein in mouse blood-brain and blood-spinal cord barriers. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism 2013, 33:381-388.
17. Chan G.N., Hoque M.T., Bendayan R. Role of nuclear receptors in the regulation of drug transporters in the brain. Trends in Pharmacological Sciences 2013, 34:361-372.
18. Chan G.N., Saldivia V., Yang Y., Pang H., de Lannoy I., Bendayan R. In vivo induction of P-glycoprotein expression at the mouse blood-brain barrier: An intracerebral microdialysis study. Journal of Neurochemistry 2013, 127:342-352.
19. Cirrito J.R., Deane R., Fagan A.M., Spinner M.L., Parsadanian M., Finn M.B., et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. The Journal of Clinical Investigation 2005, 115:3285-3290.
20. Copple I.M. The Keap1-Nrf2 cell defense pathway-A promising therapeutic target?. Advances in Pharmacology 2012, 63:43-79.
21. Copple I.M., Goldring C.E., Kitteringham N.R., Park B.K. The keap1-nrf2 cellular defense pathway: Mechanisms of regulation and role in protection against drug-induced toxicity. Handbook of Experimental Pharmacology 2010, 196:233-266.
22. Deo A.K., Borson S., Link J.M., Domino K., Eary J.F., Ke B., et al. Activity of P-glycoprotein, a beta-amyloid transporter at the blood-brain barrier, is compromised in patients with mild Alzheimer disease. Journal of Nuclear Medicine 2014, 55:1106-1111.
23. 3 reduces cerebral amyloid-β accumulation and improves cognition in mouse models of Alzheimer's disease. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2014, 34:7091-7101.
24. Feldmann M., Koepp M. P-glycoprotein imaging in temporal lobe epilepsy: In vivo PET experiments with the Pgp substrate [11C]-verapamil. Epilepsia 2012, 53(Suppl. 6):60-63.
25. Gold R., Linker R.A., Stangel M. Fumaric acid and its esters: An emerging treatment for multiple sclerosis with antioxidative mechanism of action. Clinical Immunology 2012, 142:44-48.
26. Hartz A.M., Bauer B. ABC transporters in the CNS-An inventory. Current Pharmaceutical Biotechnology 2011, 12:656-673.
27. Hartz A.M., Bauer B., Block M.L., Hong J.S., Miller D.S. Diesel exhaust particles induce oxidative stress, proinflammatory signaling, and P-glycoprotein up-regulation at the blood-brain barrier. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 2008, 22:2723-2733.
28. Hartz A.M., Bauer B., Fricker G., Miller D.S. Rapid regulation of P-glycoprotein at the blood-brain barrier by endothelin-1. Molecular Pharmacology 2004, 66:387-394.
29. Hartz A.M., Bauer B., Fricker G., Miller D.S. Rapid modulation of P-glycoprotein-mediated transport at the blood-brain barrier by tumor necrosis factor-alpha and lipopolysaccharide. Molecular Pharmacology 2006, 69:462-470.
30. Hartz A.M., Madole E.K., Miller D.S., Bauer B. Estrogen receptor beta signaling through phosphatase and tensin homolog/phosphoinositide 3-kinase/Akt/glycogen synthase kinase 3 down-regulates blood-brain barrier breast cancer resistance protein. The Journal of Pharmacology and Experimental Therapeutics 2010, 334:467-476.
31. Hartz A.M., Mahringer A., Miller D.S., Bauer B. 17-β-Estradiol: A powerful modulator of blood-brain barrier BCRP activity. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism 2010, 30:1742-1755.
32. Hartz A.M., Miller D.S., Bauer B. Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease. Molecular Pharmacology 2010, 77:715-723.
33. Hawkins B.T., Rigor R.R., Miller D.S. Rapid loss of blood-brain barrier P-glycoprotein activity through transporter internalization demonstrated using a novel in situ proteolysis protection assay. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism 2010, 30:1593-1597.
34. Hawkins B.T., Sykes D.B., Miller D.S. Rapid, reversible modulation of blood-brain barrier P-glycoprotein transport activity by vascular endothelial growth factor. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2010, 30:1417-1425.
35. Hermann D.M., Kilic E., Spudich A., Kramer S.D., Wunderli-Allenspach H., Bassetti C.L. Role of drug efflux carriers in the healthy and diseased brain. Annals of Neurology 2006, 60:489-498.
36. Hill J., Rom S., Ramirez S.H., Persidsky Y. Emerging roles of pericytes in the regulation of the neurovascular unit in health and disease. Journal of Neuroimmune Pharmacology 2014, 9:591-605.
37. Jedlitschky G., Vogelgesang S., Kroemer H.K. MDR1-P-glycoprotein (ABCB1)-mediated disposition of amyloid-beta peptides: Implications for the pathogenesis and therapy of Alzheimer's disease. Clinical Pharmacology and Therapeutics 2010, 88:441-443.
38. Kalvass J.C., Polli J.W., Bourdet D.L., Feng B., Huang S.M., Liu X., et al. Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: The ITC evidence-based position. Clinical Pharmacology and Therapeutics 2013, 94:80-94.
39. Klaassen C.D., Reisman S.A. Nrf2 the rescue: Effects of the antioxidative/electrophilic response on the liver. Toxicology and Applied Pharmacology 2010, 244:57-65.
40. Lazarowski A., Czornyj L., Lubienieki F., Girardi E., Vazquez S., D'Giano C. ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. Epilepsia 2007, 48(Suppl. 5):140-149.
41. Linker R.A., Lee D.H., Ryan S., van Dam A.M., Conrad R., Bista P., et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011, 134:678-692.
42. Lippmann E.S., Al-Ahmad A., Azarin S.M., Palecek S.P., Shusta E.V. A retinoic acid-enhanced, multicellular human blood-brain barrier model derived from stem cell sources. Scientific Reports 2014, 4:4160.
43. Lippmann E.S., Azarin S.M., Kay J.E., Nessler R.A., Wilson H.K., Al-Ahmad A., et al. Derivation of blood-brain barrier endothelial cells from human pluripotent stem cells. Nature Biotechnology 2012, 30:783-791.
44. Liu L., Wan W., Xia S., Kalionis B., Li Y. Dysfunctional Wnt/beta-catenin signaling contributes to blood-brain barrier breakdown in Alzheimer's disease. Neurochemistry International 2014, 75C:19-25.
45. Mahringer A., Fricker G. BCRP at the blood-brain barrier: Genomic regulation by 17beta-estradiol. Molecular Pharmaceutics 2010, 7:1835-1847.
46. McCaffrey G., Davis T.P. Physiology and pathophysiology of the blood-brain barrier: P-glycoprotein and occludin trafficking as therapeutic targets to optimize central nervous system drug delivery. Journal of Investigative Medicine 2012, 60:1131-1140.
47. McCaffrey G., Staatz W.D., Sanchez-Covarrubias L., Finch J.D., Demarco K., Laracuente M.L., et al. P-glycoprotein trafficking at the blood-brain barrier altered by peripheral inflammatory hyperalgesia. Journal of Neurochemistry 2012, 122:962-975.
48. Miller D.S. Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends in Pharmacological Sciences 2010, 31:246-254.
49. Miller D.S. Sphingolipid signaling reduces basal P-glycoprotein activity in renal proximal tubule. The Journal of Pharmacology and Experimental Therapeutics 2014, 348:459-464.
50. Miller D.S., Cannon R.E. Signaling pathways that regulate basal ABC transporter activity at the blood-brain barrier. Current Pharmaceutical Design 2014, 20:1463-1471.
51. Narang V.S., Fraga C., Kumar N., Shen J., Throm S., Stewart C.F., et al. Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrier. American Journal of Physiology. Cell Physiology 2008, 295:C440-C450.
52. Pinzon-Daza M.L., Salaroglio I.C., Kopecka J., Garzon R., Couraud P.O., Ghigo D., et al. The cross-talk between canonical and non-canonical Wnt-dependent pathways regulates P-glycoprotein expression in human blood-brain barrier cells. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism 2014, 34:1258-1269.
53. Potschka H. Role of CNS efflux drug transporters in antiepileptic drug delivery: Overcoming CNS efflux drug transport. Advanced Drug Delivery Reviews 2012, 64:943-952.
54. Prossnitz E.R., Barton M. Estrogen biology: New insights into GPER function and clinical opportunities. Molecular and Cellular Endocrinology 2014, 389:71-83.
55. Rigor R.R., Hawkins B.T., Miller D.S. Activation of PKC isoform beta(I) at the blood-brain barrier rapidly decreases P-glycoprotein activity and enhances drug delivery to the brain. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism 2010, 30:1373-1383.
56. Shiloh Y., Ziv Y. The ATM protein kinase: Regulating the cellular response to genotoxic stress, and more. Nature Reviews. Molecular Cell Biology 2013, 14:197-210.
57. Storch C.H., Ehehalt R., Haefeli W.E., Weiss J. Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro. The Journal of Pharmacology and Experimental Therapeutics 2007, 323:257-264.
58. van Vliet E.A., Zibell G., Pekcec A., Schlichtiger J., Edelbroek P.M., Holtman L., et al. COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats. Neuropharmacology 2010, 58:404-412.
59. Vogelgesang S., Cascorbi I., Schroeder E., Pahnke J., Kroemer H.K., Siegmund W., et al. Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 2002, 12:535-541.
60. Wang X., Campos C.R., Peart J.C., Smith L.K., Boni J.L., Cannon R.E., et al. Nrf2 upregulates ATP binding cassette transporter expression and activity at the blood-brain and blood-spinal cord barriers. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2014, 34:8585-8593.
61. Wang X., Hawkins B.T., Miller D.S. Aryl hydrocarbon receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 2011, 25:644-652.
62. Wang Y.M., Ong S.S., Chai S.C., Chen T. Role of CAR and PXR in xenobiotic sensing and metabolism. Expert Opinion on Drug Metabolism & Toxicology 2012, 8:803-817.
63. Wang X., Sykes D.B., Miller D.S. Constitutive androstane receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. Molecular Pharmacology 2010, 78:376-383.
64. Xing Y., Wang Z.H., Ma D.H., Han Y. FTY720 enhances chemosensitivity of colon cancer cells to doxorubicin and etoposide via the modulation of P-glycoprotein and multidrug resistance protein 1. Journal of Digestive Diseases 2014, 15:246-259.
65. Zhang M., An C., Gao Y., Leak R.K., Chen J., Zhang F. Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection. Progress in Neurobiology 2013, 100:30-47.
66. Zhong Y., Hennig B., Toborek M. Intact lipid rafts regulate HIV-1 Tat protein-induced activation of the Rho signaling and upregulation of P-glycoprotein in brain endothelial cells. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism 2010, 30:522-533.
67. Zibell G., Unkruer B., Pekcec A., Hartz A.M., Bauer B., Miller D.S., et al. Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition. Neuropharmacology 2009, 56:849-855.
68. Zlokovic B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008, 57:178-201.
69. Zlokovic B.V. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nature Reviews. Neuroscience 2011, 12:723-738.